Literature DB >> 11978211

Diagnosis and 10-year follow-up of a community-based hepatitis C cohort.

Barbara P Yawn1, Peter Wollan, Liliana Gazzuola, W Ray Kim.   

Abstract

OBJECTIVE: To determine the health care follow-up and treatment associated with physician-diagnosed hepatitis C (HCV) in a community-based population. STUDY
DESIGN: We conducted a retrospective medical record review using records from all providers in Olmsted County, Minnesota. POPULATION: The study incorporated all Olmsted County residents with physician-diagnosed hepatitis C from 1990 through 1999. OUTCOMES MEASURED: We assessed demographic and health status information as well as health services use in subjects with physician-diagnosed HCV.
RESULTS: Physicians diagnosed hepatitis C in 355 subjects (219 men [62%], 136 women [38%]), mean age 43 years, in the 10-year period studied. About half of diagnoses (45%, n = 159) were confirmed with polymerase chain reaction or liver biopsies. Identified risk factors included IV drug use (50%), multiple sex partners (36%), and blood transfusion (30%). Follow-up assessment with aspartate aminotransferase/amino alanine transferase (AST/ALT) tests occurred in about half (49%) of subjects, while 202 subjects (60%) were referred for gastrointestinal (GI) specialist evaluation and 49 patients (14% of all, 25% of those referred to a GI specialist) had specific treatment for hepatitis C. Although well over half of patients (60%) had possible contraindications to HCV treatment, including heavy alcohol use, few were referred for chemical dependency therapy.
CONCLUSIONS: In this community, follow-up and treatment related to HCV were limited. Attention to prevention of disease-accelerating co- infections was only modest. Referral or documented recommendations for treatment of alcoholism or heavy chronic alcohol ingestion were minimal.

Entities:  

Mesh:

Year:  2002        PMID: 11978211

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  14 in total

1.  Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008.

Authors:  Ju Dong Yang; Bohyun Kim; Schuyler O Sanderson; Jennifer L St Sauver; Barbara P Yawn; Rachel A Pedersen; Joseph J Larson; Terry M Therneau; Lewis R Roberts; W Ray Kim
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

2.  Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.

Authors:  M Lin; J Kramer; D White; Y Cao; S Tavakoli-Tabasi; S Madu; D Smith; S M Asch; H B El-Serag; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2017-09-26       Impact factor: 8.171

3.  Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users.

Authors:  Steffanie A Strathdee; M Latka; J Campbell; P T O'Driscoll; E T Golub; F Kapadia; R A Pollini; R S Garfein; D L Thomas; H Hagan
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

4.  Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in Northern California.

Authors:  Lorenzo Rossaro; Cara Torruellas; Sandeep Dhaliwal; Jacqueline Botros; Guiselle Clark; Chin-Shang Li; Mia M Minoletti
Journal:  Dig Dis Sci       Date:  2013-10-24       Impact factor: 3.199

5.  Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidence.

Authors:  Peter Higgs; Rachel Sacks-Davis; Judy Gold; Margaret Hellard
Journal:  Hepat Mon       Date:  2011-07       Impact factor: 0.660

6.  Barriers to the treatment of hepatitis C. Patient, provider, and system factors.

Authors:  James A Morrill; Melissa Shrestha; Richard W Grant
Journal:  J Gen Intern Med       Date:  2005-08       Impact factor: 5.128

7.  Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat.

Authors:  Liliana Gazzuola Rocca; Barbara P Yawn; Peter Wollan; W Ray Kim
Journal:  Ann Fam Med       Date:  2004 Mar-Apr       Impact factor: 5.166

8.  Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients.

Authors:  Maciej Witkos; Qi-Long Yi; Jenny Heathcote; Moira K Kapral; Murray D Krahn
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

9.  High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities.

Authors:  Donna M Evon; Amit Verma; Karen A Dougherty; Betty Batey; Mark Russo; Steven Zacks; Roshan Shrestha; Michael W Fried
Journal:  Dig Dis Sci       Date:  2007-03-30       Impact factor: 3.199

10.  The evaluation of patients with hepatitis C living in rural California via telemedicine.

Authors:  Lorenzo Rossaro; Christopher Aoki; Jihey Yuk; Colette Prosser; Jennifer Goforth; Frank Martinez
Journal:  Telemed J E Health       Date:  2008-12       Impact factor: 3.536

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.